The grow­ing drug dis­count pro­gram for low-in­come Amer­i­cans, known as the 340B pro­gram, has “trans­paren­cy and ...

During Thursday’s first-quarter earnings call, Chris Boerner made his strongest comments yet that Bristol Myers intends to be ...

Lotte Biologics, Ypsomed, PCI Pharma, Samsung Biologics, Catalent & Ferring share manufacturing updates: new ADC services, ...

Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff ...

Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported ...

Roche details plans to handle US tariffs, including moving production and building inventory, while Sanofi runs scenarios but ...

Tempus AI expands deals with AstraZeneca and Pathos for $200M, Avidicure raises $50M seed round, Bioxodes reports Phase 2a ...

But the company is not ruling out future deals, even in its metabolic unit, which recently saw a major partnership with ...

As­traZeneca CEO Pas­cal So­ri­ot called on Eu­rope to step up in­vest­ments and “pro­tect its health sov­er­eign­ty” as it ...

Morgan Cheatham joins Breyer Capital as healthcare head, discusses AI virtual labs' potential in drug discovery.

Versant Ventures' biotech incubation team has launched another Swiss startup, this time focused on a pair of antibodies for ...

Pfizer, Novartis, Amgen, Eli Lilly and J&J lead pharma lobbying spend amid policy changes. Issues include 340B program, drug ...